Navigation Links
Pharmaceutical Companies Lead Fight Against Staph and Other Infectious Diseases

WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- A new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA) finds that America's pharmaceutical research companies are now testing 338 new medicines to help treat infectious diseases, including 11 medicines and four vaccines to treat staphococcal infections. This is particularly important in light of increased public concern about the spread of methicillin-resistant staphylococcus aureus (MRSA) infections -- a strain of staph that has become resistant to current treatments.

"Staph poses a serious pubic health threat that we are committed to fighting," PhRMA President and CEO Billy Tauzin said. "America's pharmaceutical research companies are working hard to develop new medicines that will treat staph and even prevent patients from infection in the first place."

Although scientists say infectious diseases will never be completely eliminated, new research and commitment of resources by both the government and pharmaceutical research companies can help meet the continuing - and ever-changing - threat from infectious diseases. These 338 medicines in development will help combat humankind's oldest and most tenacious enemy: infectious diseases.

Among the new medicines now being tested are 146 vaccines to prevent diseases such as smallpox and staph; 83 antibiotics/antibacterials to treat infections such as pneumonia and tuberculosis; 75 antivirals to treat such viruses as hepatitis and influenza; and, 25 antifungals.

According to the report, the medicines in development include:

--A first-in-class medicine designed specifically to inhibit drug-resistant strains of Staphylococcus aureus.

--A medicine for the treatment of hepatitis C that is part of a new class of drugs to regulate innate immunity.

--A medicine that stops the life cycle of the bacterium that causes tuberculosis.

Other medicines are in development for treatment of fungal infections, herpes, influenza, malaria, meningitis, pneumonia, respiratory infections, rotavirus, sepsis, smallpox, and urinary tract infections, among others.

To view the report and other information about medicines in development for infectious diseases, go to:

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $43 billion in 2006 in discovering and developing new medicines. Industry wide research and investment reached a record $55.2 billion in 2006.

PhRMA Internet Address:

For information on stories of hope and survival, visit:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on the danger of imported drugs, visit:

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):